10 sources checked · 2 source groups included · 14m ago
Still Watching
FDA panel considers first-of-its-kind flu vaccine using m RNA technology
WASHINGTON (AP) — U.S. health advisers are debating a new kind of flu vaccine Thursday, the first made with the same m RNA technology that was key to ending the COVID-19 pandemic.
2 Left8 Center0 Right
Still watching.Optics is waiting for a cleaner match before calling the split.
STILL WATCHING
As of June 18, 2026 at 11:56 AM, this is how Optics News reads the wording differences in this story.
What happenedU.S. health advisers are debating a new kind of flu vaccine, the first made with the same m RNA technology that was key to ending the COVID-19 pandemic.
The headline splitThe headlines are mostly aligned. The differences are small wording choices, not a major framing split.
Match confidenceMedium confidence. 10 sources across 2 bias buckets. Useful framing signal — check the source list before sharing.
Same-event confidenceMedium
10 sources across 2 bias buckets agree on the event.
Framing confidenceMostly same
8/99 — the outlets mostly agree on the headline takeaway.
WHAT EACH SIDE EMPHASIZED
Left / center-leftFDA panel considers a first-of-its-kind flu vaccine using m RNA technology
Toronto Star · Center-left · News report
CenterFDA panel considers first-of-its-kind flu vaccine using m RNA technology
WDSU New Orleans (Hearst) · Center · News report
Right / center-rightNo matching source in this bucket yet.
FDA panel considers a first-of-its-kind flu vaccine using m RNA technology
WASHINGTON (AP) — U.S. health advisers are debating a new kind of flu vaccine Thursday, the first made with the same m RNA technology that was key to ending the COVID-19 pandemic.
FDA panel considers first-of-its-kind flu vaccine using m RNA technology
U.S. health advisers are debating a new kind of flu vaccine, the first made with the same m RNA technology that was key to ending the COVID-19 pandemic.
FDA panel considers first-of-its-kind flu vaccine using m RNA technology
U.S. health advisers are debating a new kind of flu vaccine, the first made with the same m RNA technology that was key to ending the COVID-19 pandemic.
FDA panel considers first-of-its-kind flu vaccine using m RNA technology
U.S. health advisers are debating a new kind of flu vaccine, the first made with the same m RNA technology that was key to ending the COVID-19 pandemic.
FDA panel considers first-of-its-kind flu vaccine using m RNA technology
U.S. health advisers are debating a new kind of flu vaccine, the first made with the same m RNA technology that was key to ending the COVID-19 pandemic.
FDA panel considers first-of-its-kind flu vaccine using m RNA technology
U.S. health advisers are debating a new kind of flu vaccine, the first made with the same m RNA technology that was key to ending the COVID-19 pandemic.
FDA panel considers first-of-its-kind flu vaccine using m RNA technology
U.S. health advisers are debating a new kind of flu vaccine, the first made with the same m RNA technology that was key to ending the COVID-19 pandemic.
FDA panel considers first-of-its-kind flu vaccine using m RNA technology
U.S. health advisers are debating a new kind of flu vaccine, the first made with the same m RNA technology that was key to ending the COVID-19 pandemic.
